Tango Therapeutics, a clinical-stage biotechnology company, announced a private placement to sell 15.5 million shares of its common stock, priced at USD 5.15 per share to raise USD 80 million. The financing is led by Nextech, with participation from Boxer Capital, EcoR1 Capital, and Third Rock Ventures, among others. This brings the total funds raised to USD 431 million. Further, the private placement is expected to close by August 11, 2023, subject to conditions.
The new funds will be used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications. In addition, the company believes the proceeds from this round, together with its existing cash balance, will be adequate to fund its operations till 2026.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.